elbasvir / grazoprevir

Known as: ELBASVIR/GRAZOPREVIR, elbasvir and grazoprevir 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2018
01220162018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Many direct-acting antiviral regimens have reduced activity in people with hepatitis C virus (HCV) genotype (GT)3 infection and… (More)
Is this relevant?
2017
2017
Direct-acting antiviral agents (DAAs) represent the standard of care for patients with hepatitis C virus (HCV) infection… (More)
Is this relevant?
2017
2017
Use of agents to suppress gastric acid secretion is common among patients with hepatitis C virus (HCV) infection. The aims of… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2017
2017
Direct-acting antiviral agents have not been studied exclusively in patients with inherited blood disorders and hepatitis C virus… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2017
2017
BACKGROUND The presence of baseline NS5A resistance-associated variants (RAVs) impacted treatment response in HCV genotype 1a… (More)
Is this relevant?
2017
2017
Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five… (More)
  • table 1
  • table 2
  • table 4
  • figure 1
  • table 3
Is this relevant?
2017
2017
Among patients with chronic kidney disease (CKD) in the United States, HCV infection causes significant morbidity and mortality… (More)
Is this relevant?
2016
2016
BACKGROUND & AIMS Direct-acting antiviral agents have improved treatment outcomes for patients with hepatitis C virus (HCV… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2016
Review
2016
INTRODUCTION During the last few years, treatment of hepatitis C virus (HCV) revolutionized with the appearance of direct… (More)
Is this relevant?